About Us

Welcome to Murck-Neuroscience LLC

About Us

Murck-Neuroscience LLC is a translational research company built on a unique opportunity for high-quality data generation through academic and clinical research settings. Leveraging a strong foundation at Philipps-University Marburg, Germany, where our founder, Harald Murck, holds a position as Apl. Professor, the company operates at the intersection of neuroscience, endocrinology, and translational medicine.

Our Approach

We conduct patient-centered research, with recruitment managed by medically trained students under the guidance of ethical and regulatory oversight. All studies are conducted in compliance with local ethics committees and medical research standards.

Our research is self-funded, with essential materials, including study medications and biomarker measurement devices, paid for out of pocket. Hormonal analyses are performed through an academic collaboration with Prof. Daniela Jezova at the Slovak Academy of Science, Bratislava.

Intellectual Property

All intellectual property is solely owned by Harald Murck. Since his university affiliation is non-employed, Murck-Neuroscience LLC retains full IP control, providing agility and freedom in forming new partnerships and research directions.

Collaborations & Partnerships

We maintain robust collaborations with prestigious academic institutions across Europe and the United States, including:

Philipps-University Marburg
University of Greifswald
Gutenberg University Mainz
Ludwig Maximilian University of Munich
Slovak Academy of Science, Bratislava
Massachusetts General Hospital, Harvard University
New York University

These connections support our ongoing efforts in both early-phase discovery and late-phase translational neuroscience studies.

Scientific Leadership

Our founder, Harald Murck, brings over two decades of research excellence. With more than 100 peer-reviewed publications and book chapters, he is internationally recognized for his work in neuroendocrinology, particularly on:

Aldosterone signaling in brain disorders
Glycyrrhizin and its therapeutic potential in stress-related diseases

Management Team

Our team consists of highly qualified and motivated professionals, who are all experts in their field.

Harald Murck, MD, PhD, Founder and Chief Medical Officer

Training at Max-Planck-Institute of Psychiatry Munich, Germany

25 years of Experience in Drug Development

19 years in the US

More than 100 peer reviewed publications and book chapters

Supported several programs to support regulatory approval: Inbrija (inhaled L-dopa); Vascepa (eicosapenaenoic acid); Brintilex (vortioxetine); Valdoxan (agomelatine).

Stephen Yelity, Interim Chief Executive Officer

Leader of a Biotech Accelerator

Douglas J MacNeil, Ph.D. Chief Scientific Officer

Preclinical Neuroscientist & Former CSO at several Biotech companies

Scientific Review Board Member- Alzheimer's Drug Discovery Foundation’s

Former Director, Exploratory and Translational Sciences at Merck

Advisors and Collaborators

Murck-Neuroscience’s Advisors and Collaborators is composed of world-renowned experts in psychiatry, clinical research, drug development, and pharmaceutical industry. This group provides strategic guidance and scientific rigor across all stages of development, with a focus on precision approaches to treatment-resistant depression.

David Mischoulon, MD, PhD

Director, Depression Clinical and Research Program at Massachusetts General Hospital

Dan Iosifescu, MD

Professor of Psychiatry at the New York University School of Medicine

Laura Zumpano

Vendor Oversight and Quality Process Lead, Pfizer

Marc Cantillon, MD

Profess Psychiatry RWJ< Rutgers

Consultant Drug Development and Company Builder, former VP executive Pharma at Schering Merck, Kyowa